753 related articles for article (PubMed ID: 26223655)
1. Cutting Edge: cGAS Is Required for Lethal Autoimmune Disease in the Trex1-Deficient Mouse Model of Aicardi-Goutières Syndrome.
Gray EE; Treuting PM; Woodward JJ; Stetson DB
J Immunol; 2015 Sep; 195(5):1939-43. PubMed ID: 26223655
[TBL] [Abstract][Full Text] [Related]
2. TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner.
Ablasser A; Hemmerling I; Schmid-Burgk JL; Behrendt R; Roers A; Hornung V
J Immunol; 2014 Jun; 192(12):5993-7. PubMed ID: 24813208
[TBL] [Abstract][Full Text] [Related]
3. Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases.
Gao D; Li T; Li XD; Chen X; Li QZ; Wight-Carter M; Chen ZJ
Proc Natl Acad Sci U S A; 2015 Oct; 112(42):E5699-705. PubMed ID: 26371324
[TBL] [Abstract][Full Text] [Related]
4. cGAS activation causes lupus-like autoimmune disorders in a TREX1 mutant mouse model.
Xiao N; Wei J; Xu S; Du H; Huang M; Zhang S; Ye W; Sun L; Chen Q
J Autoimmun; 2019 Jun; 100():84-94. PubMed ID: 30872080
[TBL] [Abstract][Full Text] [Related]
5. Aicardi-Goutières syndrome protein TREX1 suppresses L1 and maintains genome integrity through exonuclease-independent ORF1p depletion.
Li P; Du J; Goodier JL; Hou J; Kang J; Kazazian HH; Zhao K; Yu XF
Nucleic Acids Res; 2017 May; 45(8):4619-4631. PubMed ID: 28334850
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Cyclic GMP-AMP Synthase Using a Novel Antimalarial Drug Derivative in Trex1-Deficient Mice.
An J; Woodward JJ; Lai W; Minie M; Sun X; Tanaka L; Snyder JM; Sasaki T; Elkon KB
Arthritis Rheumatol; 2018 Nov; 70(11):1807-1819. PubMed ID: 29781188
[TBL] [Abstract][Full Text] [Related]
7. Acetylation Blocks cGAS Activity and Inhibits Self-DNA-Induced Autoimmunity.
Dai J; Huang YJ; He X; Zhao M; Wang X; Liu ZS; Xue W; Cai H; Zhan XY; Huang SY; He K; Wang H; Wang N; Sang Z; Li T; Han QY; Mao J; Diao X; Song N; Chen Y; Li WH; Man JH; Li AL; Zhou T; Liu ZG; Zhang XM; Li T
Cell; 2019 Mar; 176(6):1447-1460.e14. PubMed ID: 30799039
[TBL] [Abstract][Full Text] [Related]
8. Development of novel highly sensitive methods to detect endogenous cGAMP in cells and tissue.
Miyakawa S; Okui T; Shiraishi T; Yoshihara T; Hirayama M; Satomi Y; Hamada T; Nishida M; Akimoto C; Sato S
J Immunol Methods; 2020 May; 480():112751. PubMed ID: 31982420
[TBL] [Abstract][Full Text] [Related]
9. Dominant mutation of the TREX1 exonuclease gene in lupus and Aicardi-Goutieres syndrome.
Fye JM; Orebaugh CD; Coffin SR; Hollis T; Perrino FW
J Biol Chem; 2011 Sep; 286(37):32373-82. PubMed ID: 21808053
[TBL] [Abstract][Full Text] [Related]
10. Lack of Trex1 Causes Systemic Autoimmunity despite the Presence of Antiretroviral Drugs.
Achleitner M; Kleefisch M; Hennig A; Peschke K; Polikarpova A; Oertel R; Gabriel B; Schulze L; Lindeman D; Gerbaulet A; Fiebig U; Lee-Kirsch MA; Roers A; Behrendt R
J Immunol; 2017 Oct; 199(7):2261-2269. PubMed ID: 28835460
[TBL] [Abstract][Full Text] [Related]
11. Trex1 prevents cell-intrinsic initiation of autoimmunity.
Stetson DB; Ko JS; Heidmann T; Medzhitov R
Cell; 2008 Aug; 134(4):587-98. PubMed ID: 18724932
[TBL] [Abstract][Full Text] [Related]
12. cGAS phase separation inhibits TREX1-mediated DNA degradation and enhances cytosolic DNA sensing.
Zhou W; Mohr L; Maciejowski J; Kranzusch PJ
Mol Cell; 2021 Feb; 81(4):739-755.e7. PubMed ID: 33606975
[TBL] [Abstract][Full Text] [Related]
13. G3BP1 promotes DNA binding and activation of cGAS.
Liu ZS; Cai H; Xue W; Wang M; Xia T; Li WJ; Xing JQ; Zhao M; Huang YJ; Chen S; Wu SM; Wang X; Liu X; Pang X; Zhang ZY; Li T; Dai J; Dong F; Xia Q; Li AL; Zhou T; Liu ZG; Zhang XM; Li T
Nat Immunol; 2019 Jan; 20(1):18-28. PubMed ID: 30510222
[TBL] [Abstract][Full Text] [Related]
14. TREX1 as a Novel Immunotherapeutic Target.
Hemphill WO; Simpson SR; Liu M; Salsbury FR; Hollis T; Grayson JM; Perrino FW
Front Immunol; 2021; 12():660184. PubMed ID: 33868310
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of the immune system in Aicardi-Goutières syndrome: another example in a TREX1-mutated patient.
Olivieri I; Cattalini M; Tonduti D; La Piana R; Uggetti C; Galli J; Meini A; Tincani A; Moratto D; Fazzi E; Balottin U; Orcesi S
Lupus; 2013 Sep; 22(10):1064-9. PubMed ID: 23918923
[TBL] [Abstract][Full Text] [Related]
16. The AIM2-like Receptors Are Dispensable for the Interferon Response to Intracellular DNA.
Gray EE; Winship D; Snyder JM; Child SJ; Geballe AP; Stetson DB
Immunity; 2016 Aug; 45(2):255-66. PubMed ID: 27496731
[TBL] [Abstract][Full Text] [Related]
17. Ribonuclease H2 mutations induce a cGAS/STING-dependent innate immune response.
Mackenzie KJ; Carroll P; Lettice L; Tarnauskaitė Ž; Reddy K; Dix F; Revuelta A; Abbondati E; Rigby RE; Rabe B; Kilanowski F; Grimes G; Fluteau A; Devenney PS; Hill RE; Reijns MA; Jackson AP
EMBO J; 2016 Apr; 35(8):831-44. PubMed ID: 26903602
[TBL] [Abstract][Full Text] [Related]
18. RNase H2 catalytic core Aicardi-Goutières syndrome-related mutant invokes cGAS-STING innate immune-sensing pathway in mice.
Pokatayev V; Hasin N; Chon H; Cerritelli SM; Sakhuja K; Ward JM; Morris HD; Yan N; Crouch RJ
J Exp Med; 2016 Mar; 213(3):329-36. PubMed ID: 26880576
[TBL] [Abstract][Full Text] [Related]
19. The TREX1 exonuclease R114H mutation in Aicardi-Goutières syndrome and lupus reveals dimeric structure requirements for DNA degradation activity.
Orebaugh CD; Fye JM; Harvey S; Hollis T; Perrino FW
J Biol Chem; 2011 Nov; 286(46):40246-54. PubMed ID: 21937424
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic variation in Aicardi-Goutières syndrome explained by cell-specific IFN-stimulated gene response and cytokine release.
Cuadrado E; Michailidou I; van Bodegraven EJ; Jansen MH; Sluijs JA; Geerts D; Couraud PO; De Filippis L; Vescovi AL; Kuijpers TW; Hol EM
J Immunol; 2015 Apr; 194(8):3623-33. PubMed ID: 25769924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
